Aetna modified CPB 0345 covering implantable hormone pellets, effective February 27, 2026. Here's what billing teams need to know before submitting claims.
Aetna, a CVS Health company, updated its implantable hormone pellet coverage policy under CPB 0345 in the Aetna system. The policy governs CPT 11980 for subcutaneous hormone pellet implantation, CPT +20700 for deep drug-delivery device insertion, and HCPCS J1073 for the testosterone pellet implant itself (75 mg). If your practice bills these codes for Aetna commercial members, the criteria in this policy determine whether you get paid or face a claim denial.
Quick-Reference: Aetna CPB 0345 Implantable Hormone Pellets 2026
| Field | Detail |
|---|---|
| Payer | Aetna (Aetna, a CVS Health company) |
| Policy | Implantable Hormone Pellets — CPB 0345 |
| Policy Code | CPB 0345 |
| Change Type | Modified |
| Effective Date | February 27, 2026 |
| Impact Level | High |
| Specialties Affected | Endocrinology, Urology, Gynecology, Internal Medicine, Family Medicine, Pediatric Endocrinology |
| Key Action | Audit all Testopel (J1073, CPT 11980) claims for approved indications and confirm two documented low morning testosterone labs before submitting for hypogonadism cases |
Aetna Implantable Hormone Pellet Coverage Criteria and Medical Necessity Requirements 2026
The core of this coverage policy is narrow. Aetna covers testosterone pellets for three indications. Everything else is experimental or excluded.
Testosterone propionate implant pellets — sold as Testopel, billed under HCPCS J1073 and CPT 11980 — meet Aetna's medical necessity standard for delayed male puberty, gender dysphoria, and primary or hypogonadotropic hypogonadism. That's the full list. If your documentation doesn't map to one of those three, don't expect reimbursement.
Delayed Male Puberty
This is the simplest path to approval. The diagnosis alone (ICD-10 E30.0) satisfies the initial criteria. No additional lab thresholds or specialist consults are required beyond standard medical necessity documentation.
Gender Dysphoria (F64.0–F64.9)
This indication carries the longest checklist. To get prior authorization for Testopel under a gender dysphoria diagnosis, all six of the following must be met:
| # | Covered Indication |
|---|---|
| 1 | Confirmed gender dysphoria diagnosis |
| 2 | Member can make an informed decision about hormone therapy |
| 3 | Comorbid conditions are reasonably controlled |
| 4 | Member has been educated on contraindications and side effects |
| 5 | Fertility preservation options have been discussed before therapy starts |
| 6 | For members under 18: the prescribing provider must specialize in transgender youth care (pediatric endocrinologist, OB-GYN, family or internal medicine physician) and must collaborate with a mental health care provider; the member must also be at Tanner stage 2 or higher |
That sixth criterion is the one most practices miss on first submission. If you're billing for a minor, the records must document both the specialty of the prescribing provider and the mental health collaboration. A note from the prescriber alone won't hold up.
Primary or Hypogonadotropic Hypogonadism (E29.1, E23.0)
Aetna requires at least two confirmed low morning testosterone levels before therapy starts. Both results must fall below the reference laboratory range or align with current practice guidelines. Use CPT 84403 (total testosterone) or CPT 84402 (free testosterone) to capture those labs in the record. CPT 84410 covers bioavailable testosterone by direct measurement if that's your lab method.
One important exception: if the member has had a bilateral orchiectomy, documentation of low serum testosterone is not required. That exception needs to be explicitly noted in your prior authorization submission.
Continuation of Therapy
The continuation criteria largely mirror the initial approval criteria. For delayed puberty and gender dysphoria, new and existing members must meet all initial approval requirements each time they request reauthorization. For hypogonadism, the standard is slightly relaxed — the record just needs to show that a confirmed low morning testosterone level was documented before therapy originally started.
Aetna Implantable Hormone Pellet Exclusions and Non-Covered Indications
This section is where most denied claims originate. Aetna explicitly calls out the following as experimental, investigational, or unproven. None of these will get reimbursement under this coverage policy.
Testosterone pellets are not covered for:
| # | Excluded Procedure |
|---|---|
| 1 | Age-related or late-onset hypogonadism |
| 2 | Idiopathic hypogonadism (when not caused by testicular, pituitary, or brain disorders) |
| 3 | Male menopause (N50.89) |
| 4 | Pain management in women |
| 5 | Cancer treatment — including breast (C50.011–C50.A2), prostate (C61), and kidney cancers (C64.1–C64.9) |
Estrogen pellets are fully excluded. Aetna considers all implantable estradiol pellets experimental because they produce unpredictable and fluctuating serum estrogen levels. There is no covered indication for implantable estradiol under this policy — period. CPT 11981 for non-biodegradable drug delivery implant is listed as not covered when used to implant progestin/progesterone pellets.
Progestin/progesterone pellets are also excluded. Aetna will not cover them for dysmenorrhea (N94.4–N94.6) or erythema nodosum (L52). The evidence doesn't support these uses, and Aetna's policy reflects that directly.
The real issue here is the age-related hypogonadism exclusion. Many practices routinely bill testosterone pellet implants for older male patients with low-T symptoms. Under this policy, if the diagnosis is late-onset hypogonadism rather than primary or hypogonadotropic hypogonadism, you're billing an excluded indication. That's a claim denial waiting to happen — and potentially a compliance issue if it's a pattern.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Delayed male puberty | Covered | CPT 11980, J1073, ICD-10 E30.0 | Prior auth required; initial criteria must be met |
| Gender dysphoria | Covered | CPT 11980, J1073, F64.0–F64.9 | All six criteria must be documented; under-18 requires specialist + MH collaboration |
| Primary hypogonadism (E29.1) | Covered | CPT 11980, J1073, CPT 84402/84403 | Two confirmed low morning testosterone levels required before start |
| Hypogonadotropic hypogonadism (E23.0) | Covered | CPT 11980, J1073, CPT 84402/84403 | Same lab documentation requirement as primary hypogonadism |
| Bilateral orchiectomy | Covered (no lab req.) | CPT 11980, J1073 | Testosterone lab documentation not required |
| Continuation — delayed puberty / gender dysphoria | Covered | CPT 11980, J1073 | Must re-meet all initial approval criteria at each reauth |
| Continuation — hypogonadism | Covered | CPT 11980, J1073 | Prior low testosterone documented at original start of therapy |
| Age-related / late-onset hypogonadism | Experimental | CPT 11980, J1073 | Not covered — claim will deny |
| Idiopathic hypogonadism | Experimental | CPT 11980, J1073 | Not covered |
| Male menopause (N50.89) | Experimental | CPT 11980, J1073 | Not covered |
| Implantable estradiol pellets | Experimental | CPT 11980 | No covered indication — excluded entirely |
| Progestin/progesterone pellets | Experimental | CPT 11981 | Not covered for dysmenorrhea (N94.4–N94.6) or erythema nodosum (L52) |
| Cancer treatment (breast, prostate, kidney) | Experimental | — | Not covered under any circumstance |
| Pain management in women | Experimental | — | Not covered |
| Menopausal symptoms (N95.0–N95.9) | Experimental | — | Unlabeled and unsubstantiated use |
Aetna Implantable Hormone Pellet Billing Guidelines and Action Items 2026
The effective date is February 27, 2026. If you're billing Testopel implants for Aetna commercial members, these are your action items.
| # | Action Item |
|---|---|
| 1 | Audit your open prior authorizations for hypogonadism cases. Confirm every active auth has two documented low morning testosterone labs in the record. Use CPT 84403 or 84402 to confirm how those labs were billed. Missing documentation is the fastest path to a claim denial on continuation requests. |
| 2 | Scrub your charge capture for estradiol pellet implants. CPT 11980 billed with a menopausal or female hormone indication will deny. Implantable estradiol has zero covered indications under this policy. If your providers are implanting estrogen pellets in female patients, those claims are not going to pay under Aetna commercial plans. |
| 3 | Flag gender dysphoria cases with minor members. For any member under 18, your records must show the prescriber's specialty and documented collaboration with a mental health provider. Add a documentation checklist to your intake workflow for these cases before submitting prior auth requests. |
| 4 | Remove age-related hypogonadism from your covered diagnosis list for Testopel. ICD-10 N50.89 (male menopause) and late-onset hypogonadism are explicitly excluded. If your providers are using these diagnoses for testosterone pellet implants, update your charge capture workflow before claims go out. This is the most common miscoding pattern for this procedure. |
| 5 | Verify your +20700 addendum billing. CPT +20700, the add-on code for manual preparation and insertion of a deep drug-delivery device, is covered when selection criteria are met. Make sure this code is attached to the primary CPT 11980 when applicable — it belongs on the same claim, not as a standalone. |
| 6 | If your practice sees high volume of testosterone pellet implants, have your compliance officer review your diagnosis mix against the covered indications in CPB 0345 before the end of Q1 2026. The gap between what providers treat and what this policy covers is wide enough to create real exposure. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Implantable Hormone Pellets Under CPB 0345
Covered CPT and HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 11980 | CPT | Subcutaneous hormone pellet implantation (implantation of estradiol and/or testosterone pellets beneath the skin) |
| +20700 | CPT | Manual preparation and insertion of drug-delivery device(s), deep (e.g., subfascial) — add-on code |
| J1073 | HCPCS | Testosterone pellet, implant, 75 mg |
Not Covered / Experimental Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 11981 | CPT | Insertion, non-biodegradable drug delivery implant | Not covered when used to implant progestin/progesterone pellets |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| E23.0 | Hypopituitarism — hypogonadotropic hypogonadism (not covered for androgen deficiency due to aging or idiopathic hypogonadism) |
| E29.1 | Testicular hypofunction — primary hypogonadism (not covered for androgen deficiency due to aging or idiopathic hypogonadism) |
| E30.0 | Delayed puberty (congenital or acquired endogenous androgen absence or deficiency) |
| F64.0–F64.9 | Gender identity disorders |
| L52 | Erythema nodosum (excluded indication for progestin/progesterone pellets) |
| N50.89 | Other specified disorders of male genital organs — male menopause (excluded) |
| N91.0–N93.9 | Disorders of menstruation and other abnormal bleeding |
| N94.4–N94.6 | Dysmenorrhea (excluded indication for progestin/progesterone pellets) |
| N95.0–N95.9 | Menopausal and other perimenopausal disorders (excluded) |
| C50.011–C50.A2 | Malignant neoplasm of breast (excluded — no covered treatment indication) |
| C61 | Malignant neoplasm of prostate (excluded) |
| C64.1–C64.9 | Malignant neoplasm of kidney, except renal pelvis (excluded) |
| Z85.43 | Personal history of malignant neoplasm of ovary |
| Z87.890 | Personal history of sex reassignment |
Get the Full Picture for CPT 11980
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.